恩替卡韦
医学
危险系数
内科学
四分位间距
胃肠病学
肝硬化
置信区间
比例危险模型
乙型肝炎
失代偿
替诺福韦-阿拉芬酰胺
乙型肝炎病毒
病毒载量
免疫学
拉米夫定
病毒
抗逆转录病毒疗法
作者
Vicki Wing‐Ki Hui,Grace Lai–Hung Wong,Vincent Wai‐Sun Wong,Henry Lik‐Yuen Chan,Jimmy Che‐To Lai,Yee‐Kit Tse,Mandy Sze‐Man Lai,Tsz‐Fai Yam,Dongrong Li,Xiaodan Fan,Terry Cheuk‐Fung Yip
出处
期刊:JHEP reports
[Elsevier BV]
日期:2023-06-16
卷期号:5 (9): 100814-100814
被引量:36
标识
DOI:10.1016/j.jhepr.2023.100814
摘要
The latest Baveno VII consensus introduces the new concept of hepatic recompensation, which refers to the reversal of the structural and functional changes of cirrhosis after removal, cure, or suppression of the aetiology of cirrhosis. It is essential to investigate the transplant-free survival rates of patients who are able to achieve hepatic recompensation, as this has significant implications for the medical resources required to manage liver failure and transplantation. This study features the clinical significance of hepatic recompensation by comparing patient outcomes of those who achieve it to those who do not. The early identification and use of antiviral treatment with nucleos(t)ide analogues is a pivotal strategy to promote hepatic recompensation, which has the potential to significantly reduce mortality rates in patients with chronic HBV infection and ultimately aid in the elimination of hepatitis.
科研通智能强力驱动
Strongly Powered by AbleSci AI